# KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

> **NCT05525858** · — · RECRUITING · sponsor: **Seoul National University Bundang Hospital** · enrollment: 1000 (estimated)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor
- Metastatic Cancer

## Interventions

- **DRUG:** Alectinib
- **DRUG:** Atezolizumab
- **DRUG:** Erlotinib
- **DRUG:** Trastuzumab + Pertuzumab
- **DRUG:** Trastuzumab emtansine
- **DRUG:** Vemurafenib
- **DRUG:** Bevacizumab + Erlotinib
- **DRUG:** Entrectinib
- **DRUG:** Pralsetinib

## Key facts

- **NCT ID:** NCT05525858
- **Lead sponsor:** Seoul National University Bundang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-28
- **Primary completion:** 2026-09
- **Final completion:** 2027-03
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2025-04-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05525858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05525858, "KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05525858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*